ROBOSENSE
7.2.2020 15:02:12 CET | Business Wire | Press release
RoboSense, a leading automotive LiDAR manufacturer, announced today that it has obtained the IATF 16949 certificate in the automotive field, which now fully qualifies it to supply to automotive customers. RoboSense’s LiDAR production line obtained the IATF 16949 Letter of Conformity in December, which has accelerated partnerships of automotive-grade LiDAR serial productions with major OEMs and Tier 1s.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200207005157/en/
Developed by the IATF (International Automotive Task Force) and submitted to the International Organization for Standardization (ISO) for approval and publication, IATF 16949 is the most widely used global quality management standard for the automotive industry. In addition, the high quality management that IATF 16949 offers utilizes 5 tools (APQP/FMEA/MSA/SPC/PPAP) as part of their application assessment.
Dr. LeiLei Shinohara, the Co-partner and Vice President of RoboSense, said, "IATF16949 requires extremely high production consistency, and emphasizes various product reliability metrics. It recognizes the RoboSense design, research and development, and production processes. It also indicates that RoboSense has achieved a new milestone of complete readiness for serial mass production of automotive LiDARs, including the latest solid-state smart LiDAR "RS-LiDAR-M1".”
RoboSense's "125-layer equivalent" solid-state LiDAR "RS-LiDAR-M1" was officially released in January 2020 as the world’s first MEMS LiDAR to obtain IATF6949 for its production line. Its production was carried out under the IATF16949 quality management system.
The product development of "RS-LiDAR-M1" followed the APQP and A-SPICE as the basis for the project management and product development process. During production, RoboSense fully implemented the IATF16949 quality management system and ISO26262 functional safety standards. By combining ISO16750 test requirement and other automotive-grade reliability specifications with these systems, the accuracy of the RS-LiDAR-M1 product can be verified.
MEMS mirror is the core component in RS-LiDAR-M1. According to the AEC-Q100 standard, combining the characteristics of MEMS micro-mirror, a total of ten verification test groups were designed, covering factors such as: temperature, humidity, packaging process, electromagnetic compatibility, mechanical vibration and shock, and aging. The cumulative test time for all test samples has now exceeded 100,000 hours. Furthermore, the longest-running prototype has been tested for more than 300 days, while the total road test mileage has exceeded 150,000 kilometers with no degradation found in various testing scenarios.
In Vienna, Austria, the RS-LiDAR-M1 was tested for rain and fog under different light and wind speed conditions. The test results prove that the RS-LiDAR-M1 has met the required standards and the final mass-produced RS-LiDAR-M1 will adapt to all climate and working conditions.
RoboSense continues to optimize the LiDAR performance in order to lead the way towards a driverless future. On September 25, 2019, RoboSense partnered with First Automobile Works (FAW), the world's leading automotive OEM, to include RS-LiDAR-M1 as a core component in FAW's proprietary next-generation autonomous driving system development. On January 8, 2020, during CES2020, RoboSense cooperated with Freetech, the leading ADAS solution provider, on the serial production of the smart multi-sensor fusion solution.
About RoboSense
RoboSense (Suteng Innovation Technology Co., Ltd.) is the leading provider of Smart LiDAR Sensor Systems. By incorporating LiDAR sensors, AI algorithms and IC chipsets, conventional 3D LiDAR sensors are transformed to full data analysis and comprehension systems. The company's mission is to provide outstanding hardware and artificial intelligence capabilities to deliver smart solutions that enable robots (including vehicles) to have perception capability more superior to humans.
About IATF
IATF members include BMW Group, Daimler AG, FCA, Ford Motor Company, General Motors Company, Jaguar Land Rover (JLR) Limited, PSA Group, Renault, Volkswagen AG and the vehicle manufacturers respective trade associations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200207005157/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom